Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis
Journal of Diabetes · 2026
DOI: 10.1111/1753-0407.70206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes, 2026. Verfasst von Jiayang Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Sodium-Glucose Transporter 2 Inhibitors, Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Science Fund for Distinguished Young Scholars, Guangzhou Science and Technology Plan Project.
Abstract (Originalsprache)
MASH denotes metabolic dysfunction-associated steatohepatitis. MASH improvement was defined as a decrease in the non-alcoholic fatty liver disease activity score (NAS) of ≥ 2 points or NAS ≤ 3 at week 48 after treatment, with no worsening of fibrosis (i.e., no increase in fibrosis stage). MASH resolution was defined as a hepatocellular ballooning score of 0 and a lobular inflammation score of 0 or 1 at week 48, with no worsening of fibrosis. Fibrosis improvement was defined as a reduction in fibrosis of ≥ 1 stage at week 48, with no worsening of MASH (i.e., no increase in steatosis, ballooning, or inflammation scores).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- School of Public Health, Southern Medical University, Guangzhou, China.
- Key Laboratory of Functional and Clinical Translational Medicine, Department of General Medicine, Xiamen Medical College, Xiamen, China.
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Huijie Zhang
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Science Fund for Distinguished Young Scholars
- Guangzhou Science and Technology Plan Project
- Xiamen Municipal Medical and Health Science and Technology Program
- Fujian Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
- Joint Funds of the National Natural Science Foundation of China
Zitieren
APA
Lin, J., Huang, Y., Xu, B., Huang, C., Teng, F., Yuan, Y., Zhang, J., & Zhang, H. (2026). Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70206
Vancouver
Lin J, Huang Y, Xu B, Huang C, Teng F, Yuan Y, et al. Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis. Journal of Diabetes. 2026. doi:10.1111/1753-0407.70206
BibTeX
@article{Lin2026,
author = {Lin, Jiayang and Huang, Yan and Xu, Bingyan and Huang, Chensihan and Teng, Fei and Yuan, Youwen and Zhang, Jinhua and Zhang, Huijie},
title = {Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis},
journal = {Journal of Diabetes},
year = {2026},
doi = {10.1111/1753-0407.70206}
}
EUVIMED